ProfileGDS5678 / 1455389_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 85% 85% 88% 87% 79% 88% 86% 84% 86% 85% 87% 87% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9442482
GSM967853U87-EV human glioblastoma xenograft - Control 26.4721185
GSM967854U87-EV human glioblastoma xenograft - Control 36.3790385
GSM967855U87-EV human glioblastoma xenograft - Control 47.0093688
GSM967856U87-EV human glioblastoma xenograft - Control 56.6784887
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3611779
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.603488
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.509586
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2217484
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6097486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.375185
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.6783987
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7154687
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6773987